Alzheimer’s and Memory Loss Clinical Studies

Imagine your body is like a car, and you want to know how it's running. A biomarker is like a gauge or a warning light on the dashboard, something measurable that may indicate if you have a disease, how well a treatment is working, or if you're at risk for a future health problem.

The purpose of this end-of-life study is to evaluate the effectiveness of a new brain (PET) scan in accurately detecting Alzheimer’s disease. We hope that earlier, more accurate detection of Alzheimer’s disease will one day allow patients to confirm their diagnosis more easily, and then they can confidently begin new treatments that may delay—or eventually even reverse—the progression of the disease.

The investigational drug was developed in response to evidence of a strong association between chronically-raised cortisol levels and the development of cognitive impairment in Alzheimer’s disease. The drug is designed to target and block production of cortisol inside brain neurons.

The purpose of this early Alzheimer's study is to find out if the study drug can possibly prevent, delay, or slow early symptoms of Alzheimer’s disease.

Patients with mild to moderate Alzheimer’s disease often have negative changes in how efficiently their bodies process dopamine, a neurotransmitter that helps nerve cells send messages to each other. This can lead to adverse changes in personality, mood, and behavior. This investigational drug enhances the body’s ability to utilize dopamine.

Agitation in all its forms—from finger tapping, nail biting and restlessness to excessive motor activity, verbal aggression, or even physical aggression—is particularly challenging because there are currently no effective treatments for it.

Nearly one in five Americans over the age of 60 experience subtle downturns in memory, thinking, and cognition. Clinically, this fading of cognitive abilities is...

Scientists have linked the progression of Alzheimer’s to the buildup of certain kinds of protein in the brain. Sometimes, these proteins malfunction and gum up...

Asthma drugs, cancer drugs, even obesity drugs, are all being explored for their potential in treating the pathology and symptoms of Alzheimer’s disease. Finding the...

Research has established that women are twice as likely to develop Alzheimer’s, but—despite study after study into this sex-based disparity in Alzheimer’s risk—scientists are still...

Symptom management in Alzheimer’s helps people remain independent for longer. Alzheimer’s disease is a progressive neurodegenerative condition that affects more than one in every 9...

Charter Research is recruiting for a new Phase 3 trial for Alzheon’s new drug, which aims to be the first oral disease-modifying therapy for Alzheimer’s....